Anti-Saccharomyces Cerevisiae as Unusual Antibody in Autoimmune Polyglandular Syndrome Type III: A Case Report

Author(s): Ahmet Gorgel*, Cem Cankaya, Mehmet Tecellioglu.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 19 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Backgraund and Objective: Anti-Saccharomyces Cerevisiae Antibodies (ASCA) that are considered to reflect immune response against increased intestinal permeability due to mucosal damage are among the serological markers of Crohn’s Disease.

Methods: This microbial seromarker was recently shown to be elevated in several autoimmune disorders such as celiac disease, autoimmune liver diseases, type 1 diabetes, and Graves’ disease. Despite that fact, ASCA seropositivity in Autoimmune Polyglandular Syndrome (APS) has never been reported before.

Results: Herein, we present a 46-year-old woman who has uveitis, autoimmune thyroiditis, and primary ovarian failure.

Conclusion: Based on the coexistence of these diseases, the patient was diagnosed with APS type III. Moreover, ASCA seropositivity was detected although she has no overt intestinal disease.

Keywords: Anti-Saccharomyces Cerevisiae Antibody (ASCA), Autoimmune Polyglandular Syndrome (APS) type III, uveitis, anti-double-stranded DNA, autoimmune hepatititis, antinuclear antibody.

[1]
Neufeld, M.; Blizzard, R.M. Polyglandular autoimmune disease. In: Pinchera, A.; Doniach, D.; Fenzi, D.F.; Baschieri, L. (eds.). Autoimmune aspects of endocrine disorders. London, UK, Academic Press,, 1980, 357-365.
[2]
Eisenbarth, G.S.; Gottlieb, P.A. Autoimmune polyendocrine syndromes. N. Engl. J. Med., 2004, 350, 2068-2079.
[3]
Kasznicki, J.; Drzewoski, J. A case of autoimmune urticaria accompanying autoimmune polyglandular syndrome type III associated with Hashimoto’s disease, type 1 diabetes mellitus, and vitiligo. Endokrynol. Pol., 2014, 65(4), 320-323.
[4]
McKenzie, H.; Main, J.; Pennington, C.R.; Parratt, D. Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and Candida albicans in Crohn’s disease. Gut, 1990, 31, 536-538.
[5]
Vasiliauskas, E.A.; Kam, L.Y.; Karp, L.C.; Gaiennie, J.; Yang, H.; Targan, S.R. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut, 2000, 47, 487-496.
[6]
Arnott, I.D.; Landers, C.J.; Nimmo, E.J.; Drummond, H.E.; Smith, B.K.; Targan, S.R.; Satsangi, J. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol., 2004, 99, 2376-2384.
[7]
Viitasalo, L.; Niemi, L.; Ashorn, M.; Ashorn, S.; Braun, J.; Huhtala, H.; Collin, P.; Mäki, M.; Kaukinen, K.; Kurppa, K.; Iltanen, S. Early Microbial Markers of Celiac Disease. J. Clin. Gastroenterol., 2014, 48(7), 620-624.
[8]
Fagoonee, S.; De Luca, L.; De Angelis, C.; Castelli, A.; Rizzetto, M.; Pellicano, R. Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol. Dietol., 2009, 55(1), 37-40.
[9]
Maillet, J.; Ottaviani, S.; Tubach, F.; Roy, C.; Nicaise-Rolland, P.; Palazzo, E.; Dieudé, P. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthritis: Prevalence and associated phenotype. Joint Bone Spine, 2016, 83(6), 665-668.
[10]
Sakly, W.; Mankaï, A.; Sakly, N.; Thabet, Y.; Achour, A.; Ghedira-Besbes, L.; Jeddi, M.; Ghedira, I. Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes. Endocr. Pathol., 2010, 21(2), 108-114.
[11]
Krause, I.; Monselise, Y.; Milo, G.; Weinberger, A. Anti-Saccharomyces cerevisiae antibodies--a novel serologic marker for Behçet’s disease. Clin. Exp. Rheumatol., 2002, 20(4)(Suppl. 26), 21-24.
[12]
Yazıcı, D.; Aydın, S.Z.; Yavuz, D.; Tarçın, O.; Deyneli, O.; Direskeneli, H.; Akalın, S. Anti-Saccaromyces cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease. Endocrine, 2010, 38(2), 194-198.
[13]
Salehi-Abari, I. Letter to Editor. 2015 ACR/SLICC Revised Criteria for Diagnosis of Systemic Lupus Erythematosus. Autoimmune Dis. Ther. Approaches, 2015, 2, 114.
[14]
North American Menopause Society.. Early menopause guidebook,, 2006. 6th edition. Cleveland, OH, North American Menopause Society .
[15]
Kalu, E.; Panay, N. Spontaneous premature ovarian failure: management challenges. Gynecol. Endocrinol., 2008, 24, 273-279.
[16]
McLean, M.H.; Dieguez, D., Jr; Miller, L.M.; Young, H.A. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut, 2015, 64, 332-341.
[17]
Horai, R.; Zárate-Bladés, C.R.; Dillenburg-Pilla, P.; Chen, J.; Kielczewski, J.L.; Silver, P.B.; Jittayasothorn, Y.; Chan, C.C.; Yamane, H.; Honda, K.; Caspi, R.R. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity, 2015, 43, 343-353.
[18]
Hube, B. Fungal adaptation to the host environment. Curr. Opin. Microbiol., 2009, 12, 347-349.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Page: [90 - 94]
Pages: 5
DOI: 10.2174/1871530318666180817143536
Price: $58

Article Metrics

PDF: 21
HTML: 2